Atara Biotherapeutics Inc. (ATRA)
$9.76
$0.23
(2.41%)
As on 04-Sep-2026 19:52EDT
Market cap
$98 Mln
Revenue (TTM)
$6 Mln
P/E Ratio
--
P/B Ratio
16.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-20.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
2.2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.2
-
Face value
--
-
Shares outstanding
10,037,710
10 Years Aggregate
CFO
$-1,481.40 Mln
EBITDA
$-2,037.01 Mln
Net Profit
$-1,956.63 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Atara Biotherapeutics (ATRA)
| -46.0 | 14.2 | 1.3 | -22.7 | -36.8 | -52.1 | -32.4 |
|
BSE Sensex*
| -10.1 | -3.6 | 2.5 | -5.7 | 4.9 | 5.5 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Atara Biotherapeutics (ATRA)
| 35.9 | 3.8 | -84.4 | -79.2 | -19.7 | 19.2 | -52.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Atara Biotherapeutics (ATRA)
|
9.8 | 98.0 | 6.2 | -16.7 | -223.4 | -- | -- | 16.1 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 270.6 | 17,746.8 | 1,054.4 | 755.9 | 5.7 | -- | 20.9 | 10.5 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 |
Shareholding Pattern
View DetailsAbout Atara Biotherapeutics (ATRA)
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy... program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California. Read more
-
President, CEO & Director
Dr. Pascal Touchon D.V.M.
-
President, CEO & Director
Dr. Anhco Nguyen Ph.D.
-
Headquarters
Thousand Oaks, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Atara Biotherapeutics (ATRA)
What is the current share price of Atara Biotherapeutics Inc (ATRA) Today?
The share price of Atara Biotherapeutics Inc (ATRA) is $9.76 (NASDAQ) as of 04-Sep-2026 19:52 EDT. Atara Biotherapeutics Inc (ATRA) has given a return of -36.85% in the last 3 years.
What is the current PB & PE ratio of Atara Biotherapeutics Inc (ATRA)?
Since, TTM earnings of Atara Biotherapeutics Inc (ATRA) is negative, P/E ratio is not available.
The P/B ratio of Atara Biotherapeutics Inc (ATRA) is 16.14 times as on 04-Sep-2026, a 203 premium to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
7.04 |
-5.98 |
2024 |
-1.67 |
-1.46 |
2023 |
-0.01 |
-0.02 |
2022 |
-0.06 |
0.11 |
2021 |
-0.18 |
0.22 |
What is the 52 Week High and Low of Atara Biotherapeutics Inc (ATRA)?
The 52-week high and low of Atara Biotherapeutics Inc (ATRA) are Rs 19.15 and Rs 3.92 as of 08-Sep-2026.
What is the market cap of Atara Biotherapeutics Inc (ATRA)?
Atara Biotherapeutics Inc (ATRA) has a market capitalisation of $ 98 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Atara Biotherapeutics Inc (ATRA)?
Before investing in Atara Biotherapeutics Inc (ATRA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.